View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 3, 2019

Biocorp seeks to use Mallya device with Sanofi diabetes platform

Biocorp has entered into exclusive negotiations to connect its Mallya device with pharmaceutical company Sanofi’s diabetes care platform.

BIOCORP has entered into exclusive negotiations to connect its Mallya device with pharmaceutical company Sanofi ’s diabetes care platform.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

Part of BIOCORP ’s connected devices portfolio, Mallya is a smart sensor cap that can be clipped onto an insulin injection pen for automatic recording and the transmission of dosage information.

The device sends the captured information to a companion mobile application in real-time via Bluetooth technology.

The Mallya connected device can be reused for two years and provides track records of dose delivered, insulin type, and time and date for each injection.

The device, which can be used with existing platforms and digital solutions, comes with audio and visual signals intended to guide patients during the injection process.

Last month, BIOCORP secured the European CE-Mark for Mallya as a class IIb medical device.

As per the terms of the exclusive negotiations with Sanofi , French firm BIOCORP will initially receive a payment of €4m to support related development activities.

BIOCORP chief operating officer Eric Dessertenne said: “We are proud to bring a breakthrough device to the market to improve the daily lives of patients with diabetes.

“We believe our innovative Mallya has great potential to become the standard in its class and should contribute significantly, and in a short time, to our very strong growth.”

The company, founded in 2004, develops medical devices and also smart drug delivery systems. BIOCORP ‘s connected devices portfolio also includes Inspair, OneJet and Datapen.

Inspair is a smart cap designed to automatically capture each actuation of an inhaler and analyse the device’s usage.

OneJet is a Bluetooth-enabled motor driven auto-injector for the delivery of high viscosity products, while Datapen is a smart pen injector meant to facilitate easy treatment delivery.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network